Shots:

• Zydus to advance the new IO therapies through formal clinical studies and receives exclusive rights to develop and commercialize the therapy in India- Brazil- Mexico and other emerging markets
• XOMA retains the rights for all other territories and receives royalties on the sales in the licensed territories. The collaboration will combine Zydus’ IL-2 with XOMA’s anti-IL-2 mAb
• Zydus to develop new IO therapy through human POC while each company will receive pre-defined shares of future proceeds that may arise under the license agreement

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Zydus